+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years +
All Genders
ID06652438

Randomized Study Evaluating Revumenib Combined With Azacitidine and Venetoclax in Adults With Newly Diagnosed NPM1-Mutated or KMT2A-Rearranged AML Not Eligible for Intensive Chemotherapy

Led by Stichting Hemato-Oncologie voor Volwassenen Nederland · Updated on 2026-09-02

448

Participants Needed

201

Research Sites

141 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are investigating a new treatment approach for adults with newly diagnosed acute myeloid leukemia AML who have specific genetic mutations NPM1 or KMT2A and are not eligible for intensive chemotherapy. Although current treatment combining azacitidine and venetoclax has improved outcomes, it is not curative and relapses occur. This Phase 3 study aims to determine if adding the investigational drug revumenib, which blocks a molecule called menin involved in leukemia cell production, can improve patient prognosis. Participants will be randomly assigned to receive either revumenib or a placebo, both in combination with azacitidine and venetoclax. Treatment cycles last 28 days and continue until the disease progresses, unacceptable side effects develop, death occurs, or other protocol criteria require stopping treatment. After the last patient joins the study, there will be a 4-year follow-up period to monitor survival and conduct additional visits. During the study, participants will undergo regular assessments to evaluate overall survival, remission rates, event-free survival, quality of life, and molecular responses using bone marrow and blood tests. Safety and treatment effects will be closely monitored throughout the treatment and follow-up periods. Participants must be adults with confirmed mutations and meet specific health criteria to join this trial.

CONDITIONS

Brief Title

Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML

Research Team

G

Gerwin Huls, MD

P

Paresh Vyas, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here